MY152271A - Novel compounds that are erk inhibitors - Google Patents

Novel compounds that are erk inhibitors

Info

Publication number
MY152271A
MY152271A MYPI20103904A MY152271A MY 152271 A MY152271 A MY 152271A MY PI20103904 A MYPI20103904 A MY PI20103904A MY 152271 A MY152271 A MY 152271A
Authority
MY
Malaysia
Prior art keywords
novel compounds
erk inhibitors
formula
disclosed
erk
Prior art date
Application number
Other languages
English (en)
Inventor
Alan B Cooper
Mehul F Patel
Jagdish A Desai
James J-S Wang
Paliwal Sunil
Tsui Hon-Chung
Boga Sobhana Babu
Alhassan Abdul-Basit
Gao Xiaolei
Zhu Liang
Yao Xin
Nan Yang
Deng Yongqi
Gerald W Shipps Jr
Shin Neng-Yang
Hugh Y Zhu
Joseph M Kelly
Gudipati Subrahmanyam
Ronald J Doll
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY152271(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MY152271A publication Critical patent/MY152271A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20103904 2008-02-21 2009-02-19 Novel compounds that are erk inhibitors MY152271A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21

Publications (1)

Publication Number Publication Date
MY152271A true MY152271A (en) 2014-09-15

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20103904 MY152271A (en) 2008-02-21 2009-02-19 Novel compounds that are erk inhibitors

Country Status (23)

Country Link
US (1) US8716483B2 (Direct)
EP (1) EP2260031B1 (Direct)
JP (1) JP5276676B2 (Direct)
KR (1) KR20100117123A (Direct)
CN (1) CN102015693B (Direct)
AR (1) AR070460A1 (Direct)
AU (1) AU2009215534B8 (Direct)
BR (1) BRPI0908120A8 (Direct)
CA (1) CA2714479A1 (Direct)
CL (1) CL2009000394A1 (Direct)
CO (1) CO6300939A2 (Direct)
EC (1) ECSP10010415A (Direct)
ES (1) ES2556353T3 (Direct)
IL (1) IL207530A (Direct)
MX (1) MX2010009268A (Direct)
MY (1) MY152271A (Direct)
NZ (1) NZ587504A (Direct)
PE (1) PE20091491A1 (Direct)
RU (1) RU2525389C2 (Direct)
SG (1) SG188179A1 (Direct)
TW (1) TWI398441B (Direct)
WO (1) WO2009105500A1 (Direct)
ZA (2) ZA201005909B (Direct)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
WO2010021978A2 (en) * 2008-08-19 2010-02-25 Schering Corporation Il-8 biomarker
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011002887A1 (en) 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
WO2011163330A1 (en) * 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP2630133A1 (de) 2010-10-22 2013-08-28 Bayer Intellectual Property GmbH Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
JP2014500874A (ja) * 2010-11-16 2014-01-16 メディミューン，エルエルシー 抗ｉｇｆ抗体を用いた治療レジメン
WO2013015918A1 (en) 2011-07-22 2013-01-31 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
LT3321262T (lt) 2012-03-01 2021-06-10 Array Biopharma, Inc. Serino/treonino kinazės inhibitoriai
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
MX2015000830A (es) 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
US9226922B2 (en) 2012-09-28 2016-01-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
MX2015004041A (es) * 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
RU2018109979A (ru) * 2013-03-13 2019-02-28 Ф. Хоффманн-Ля Рош Аг Способ получения бензоксазепиновых соединений
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
CA2924584A1 (en) 2013-10-03 2015-04-09 Kura Oncology, Inc. Inhibitors of erk and methods of use
EP3143166A4 (en) 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
KR20170095972A (ko) * 2014-12-18 2017-08-23 머크 샤프 앤드 돔 코포레이션 제약 제제용 (s)-n-(3-(6-이소프로폭시피리딘-3-일)-1h-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2h)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 조성물
CA2971088A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
DK3277690T3 (da) 2015-04-03 2020-05-04 Recurium Ip Holdings Llc Spirocykliske forbindelser
WO2017040362A1 (en) * 2015-09-03 2017-03-09 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
TW202128664A (zh) 2019-10-09 2021-08-01 德商拜耳廠股份有限公司 作為除害劑之新穎雜芳基三唑化合物
EP4071152B1 (en) 2019-12-06 2025-03-05 D3 Bio (Wuxi) Co., Ltd. Spiro compound serving as erk inhibitor, and application thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
WO1999003498A1 (en) 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AU2001236720A1 (en) 2000-02-05 2001-08-14 Bemis, Guy Compositions useful as inhibitors of erk
SK14082001A3 (sk) 2000-02-05 2002-03-05 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
JP2003527379A (ja) 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
PE20020451A1 (es) 2000-09-15 2002-06-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de cinasa proteina
HK1052934B (en) 2000-09-15 2007-01-12 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
DE60125980T2 (de) 2000-11-20 2007-10-25 Scios Inc., Sunnyvale P38kinase-inhibitoren vom piperidin/piperazin-typ
US6653301B2 (en) 2000-12-21 2003-11-25 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CA2440842A1 (en) 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
CA2445357A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
DE60226154T2 (de) 2001-08-03 2009-05-20 Vertex Pharmaceuticals Inc., Cambridge Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
WO2003011854A1 (en) 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
WO2003035626A2 (en) 2001-10-23 2003-05-01 Applied Research Systems Ars Holding N.V. Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4845379B2 (ja) 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
CA2522176A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
EP1791831A4 (en) 2003-11-19 2009-07-08 Signal Pharm Llc METHOD FOR THE TREATMENT OF DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES
AU2004308974A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
JP2007530595A (ja) 2004-03-26 2007-11-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋ２のピリジンインヒビターおよびそれらの使用
EP1756082A1 (en) 2004-04-13 2007-02-28 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
ZA200610163B (en) 2004-05-14 2008-02-27 Vertex Pharma Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
CA2566461C (en) 2004-05-14 2012-07-10 Gabriel Martinez-Botella Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
WO2006071644A1 (en) 2004-12-23 2006-07-06 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinases and uses therof
CN100377868C (zh) 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
SI1966151T1 (sl) * 2005-12-13 2012-02-29 Schering Corp Policikliäśni indazol derivati, ki so erk inhibitorji
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
US20090062355A1 (en) 2006-04-20 2009-03-05 Takeda Pharmaceutical Company Limited Pharmaceutical Product
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
US7671832B2 (en) 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
CA2874756C (en) 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
PE20090326A1 (es) * 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
JP5451602B2 (ja) 2007-06-08 2014-03-26 アッヴィ・インコーポレイテッド キナーゼ阻害薬としての５−ヘテロアリール置換インダゾール類
WO2008156739A1 (en) 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
WO2011041152A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors

Also Published As

Publication number Publication date
CN102015693B (zh) 2014-10-29
AU2009215534A8 (en) 2014-07-10
JP5276676B2 (ja) 2013-08-28
US8716483B2 (en) 2014-05-06
NZ587504A (en) 2012-09-28
EP2260031B1 (en) 2015-10-07
BRPI0908120A8 (pt) 2017-10-24
TW200948799A (en) 2009-12-01
ZA201005909B (en) 2014-03-26
JP2011513225A (ja) 2011-04-28
BRPI0908120A2 (Direct) 2017-08-22
EP2260031A1 (en) 2010-12-15
CA2714479A1 (en) 2009-08-27
AU2009215534A1 (en) 2009-08-27
AU2009215534B2 (en) 2014-06-26
IL207530A (en) 2014-08-31
IL207530A0 (en) 2010-12-30
CN102015693A (zh) 2011-04-13
ZA201400396B (en) 2014-12-23
WO2009105500A1 (en) 2009-08-27
PE20091491A1 (es) 2009-09-25
TWI398441B (zh) 2013-06-11
MX2010009268A (es) 2010-09-14
ES2556353T8 (es) 2017-10-13
ECSP10010415A (es) 2010-09-30
AU2009215534B8 (en) 2014-07-10
AU2009215534A2 (en) 2010-12-23
RU2010138635A (ru) 2012-03-27
AR070460A1 (es) 2010-04-07
SG188179A1 (en) 2013-03-28
KR20100117123A (ko) 2010-11-02
ES2556353T3 (es) 2016-01-15
CL2009000394A1 (es) 2011-02-11
RU2525389C2 (ru) 2014-08-10
US20110189192A1 (en) 2011-08-04
CO6300939A2 (es) 2011-07-21

Similar Documents

Publication Publication Date Title
MY152271A (en) Novel compounds that are erk inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
MX2009009786A (es) Inhibidores de la via de hedgehog.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
GEP20115304B (en) PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
MY180812A (en) 4'-o-substituted isoindoline derivattives and compositions comprising and methods of using the same
JO2892B1 (en) CYP inhibitors 17
PH12014501082A1 (en) Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
MX2009014208A (es) Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
PH12014500599B1 (en) Protein kinase inhibitors
TW200738725A (en) Unsaturated mTOR inhibitors
TW200745089A (en) Novel compounds that are ERK inhibitors
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
MX2009005795A (es) Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona.
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
IN2012DN03182A (Direct)
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
EA200970936A1 (ru) СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА
WO2012058127A3 (en) Novel compounds that are erk inhibitors
MX2013007892A (es) Derivados de fenetilsulfona isoindolina y su uso.
PH12020552261A1 (en) Proteasome activity enhancing compounds